Poster

Efficacy and Safety Outcomes When Transitioning to Paliperidone Palmitate 6-Month From Paliperidone Palmitate 1-Month Versus Paliperidone Palmitate 3-Month

This post hoc analysis of a non-inferiority study (NCT03345342) found that adult patients with schizophrenia who transition to palmitate 6-month (PP6M) from either paliperidone palmitate ...

10/26/2023

Efficacy and Safety Results from the Confirmatory Phase 3 Randomized, Placebo-Controlled Trial of MDMA-Assisted Therapy for Treatment of Chronic PTSD With at Least Moderate Severity

Posttraumatic stress disorder (PTSD) is a serious neuropsychiatric illness for which novel treatment options are urgently needed. This multi-site, randomized, double-blind, confirmatory p...

10/26/2023

Effects of Solriamfetol on Cognition in Participants with Cognitive Impairment Associated with Excessive Daytime Sleepiness in Obstructive Sleep Apnea: SHARP Study Results

The SHARP trial evaluated solriamfetol's effect on cognitive function in patients with obstructive sleep apnea (OSA) and excessive daytime sleepiness (EDS)-related cognitive impairment. T...

10/26/2023

Efficacy and Engagement With a Digital Therapeutic in Patients With Experiential Negative Symptoms of Schizophrenia

Currently, there are no effective pharmacotherapies approved for experiential negative symptoms (ENS) of schizophrenia. Digital therapeutics (DTx) may represent a feasible option given ub...

10/26/2023

Efficacy and Safety of Iclepertin (BI 425809) in Patients with Schizophrenia: CONNEX, a Phase III Randomized Controlled Trial Program

Cognitive impairment is a major determinant of poor functional outcomes in schizophrenia. Currently, studies testing potential treatments for cognitive impairment have failed to demonstra...

10/26/2023

Efficacy and Safety of Paliperidone Palmitate 6-Month Formulation: A 3-Year Analysis in Adults With Schizophrenia

This analysis assessed the efficacy and safety of paliperidone palmitate 6-month (PP6M) in adults with schizophrenia who remained relapse free after a 1-year double-blind study (NCT033453...

10/26/2023

EEG Individual Alpha Frequencies May Improve Depression Symptoms in TMS Treatment

69 patients were grouped based on their baseline individual alpha frequency (IAF): 8, 9, 10, or 11 Hz. We show the percentage of patients in each group that reported a decrease, increase,...

10/26/2023

Effect of Adjunctive Cariprazine on Symptoms of Anhedonia in Patients with Major Depressive Disorder

Results from this post-hoc analysis suggest adjunctive cariprazine treatment may be effective for improving symptoms of anhedonia in patients with major depressive disorder.

10/26/2023

Effectiveness of Vortioxetine in Elderly Patients With Major Depressive Disorder in Real-World Clinical Practice: Results From the RELIEVE Study

This subgroup analysis of the RELIEVE study evaluated effectiveness and tolerability of vortioxetine for treatment of major depressive disorder (MDD) in elderly patients. Elderly patients...

10/26/2023

Effectiveness of Vortioxetine in Patients With Major Depressive Disorder and Early-Stage Dementia: The MEMORY Study

The MEMORY study demonstrates the effectiveness of vortioxetine in clinically significantly improving depressive symptoms, cognitive performance, daily functioning, and HRQoL, as well as ...

10/26/2023